Ataxia Telangiectasia
28
0
2
10
Key Insights
Highlights
Success Rate
77% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
10.7%
3 terminated out of 28 trials
76.9%
-9.6% vs benchmark
14%
4 trials in Phase 3/4
40%
4 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (28)
Open-Label Extension of EryDex Study IEDAT-04-2022
Evaluate the Neurological Effects of EryDex on Subjects With A-T
The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
N-Acetyl-L-Leucine for Ataxia-Telangiectasia (A-T)
Safety and Efficacy of Mutation-targeted Precision Genetic Therapy for Ataxia-Telangiectasia (A-T)
Extension Treatment Using EryDex System in Patients With AT Who Participated in the ATTeST-IEDAT-02-2015 Study
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside
Whole Body MRI for Cancer Surveillance in A-T
Home-based Complex Intervention for Children With Ataxia Telangiectasia
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With a Novel Form of Anaplerosis
Comparative Bioavailability of Betamethasone Oral Solution Metered Spray (GTX-102) in Healthy Subjects
NAD Supplementation to Prevent Progressive Neurological Disease in Ataxia Telangiectasia
Effects of Vitamin B3 in Patients With Ataxia Telangiectasia
Videoocular Assessment of Eye Movement Activity in an Ataxia Telangiectasia
A National Retrospective Population Based Cohort Study of the Natural History of Ataxia Telangiectasia
Treatment of Leukemia and Lymphoma in Children With Ataxia Telangiectasia
Oxidative Stress, Low Grade Inflammation, Tissue Breakdown and Biomarkers in Cerebrospinal Fluid of A-T
MBM-01 (Tempol) for the Treatment of Ataxia Telangiectasia
Neurofilament Light- Chain in Ataxia Telangiectasia
Pancreatic Cancer Screening of High-Risk Individuals in Arkansas